key: cord-0923043-0cpv0lly
authors: Loveys, Kate; Prina, Matthew; Axford, Chloe; Domènec, Òscar Ristol; Weng, William; Broadbent, Elizabeth; Pujari, Sameer; Jang, Hyobum; Han, Zee A; Thiyagarajan, Jotheeswaran Amuthavalli
title: Artificial intelligence for older people receiving long-term care: a systematic review of acceptability and effectiveness studies
date: 2022-04-03
journal: Lancet Healthy Longev
DOI: 10.1016/s2666-7568(22)00034-4
sha: 7aa125317064942543723cbc817ad932dc692ab6
doc_id: 923043
cord_uid: 0cpv0lly

Artificial intelligence (AI)-enhanced interventions show promise for improving the delivery of long-term care (LTC) services for older people. However, the research field is developmental and has yet to be systematically synthesised. This systematic review aimed to synthesise the literature on the acceptability and effectiveness of AI-enhanced interventions for older people receiving LTC services. We conducted a systematic search that identified 2720 records from Embase, Ovid, Global Health, PsycINFO, and Web of Science. 31 articles were included in the review that evaluated AI-enhanced social robots (n=22), environmental sensors (n=6), and wearable sensors (n=5) with older people receiving LTC services across 15 controlled and 14 non-controlled trials in high-income countries. Risk of bias was evaluated using the RoB 2, RoB 2 CRT, and ROBINS-I tools. Overall, AI-enhanced interventions were found to be somewhat acceptable to users with mixed evidence for their effectiveness across different health outcomes. The included studies were found to have high risk of bias which reduced confidence in the results. AI-enhanced interventions are promising innovations that could reshape the landscape of LTC globally. However, more trials are required to support their widespread implementation. Pathways are needed to support more high-quality trials, including in low-income and middle-income countries.

9 Specify the methods used to collect data from reports, including how many reviewers collected data from each report, whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process.

10 Data items 10a List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which results to collect.

10b List and define all other variables for which data were sought (e.g. participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information.

10 Study risk of bias assessment 11 Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the process.

Effect measures 12 Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of results. 10

Synthesis methods 13a Describe the processes used to decide which studies were eligible for each synthesis (e.g. tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item #5)).

13b Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data conversions.

2

Location where item is reported 13c Describe any methods used to tabulate or visually display results of individual studies and syntheses. 10

13d Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used.

13e Describe any methods used to explore possible causes of heterogeneity among study results (e.g. subgroup analysis, meta-regression). n/a 13f Describe any sensitivity analyses conducted to assess robustness of the synthesized results. n/a

Reporting bias assessment 14 Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases). 10

Certainty assessment 15 Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome. 10

16a Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram.

10, Figure 1 16b Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded. 10, 21

Study characteristics 17 Cite each included study and present its characteristics. 10-11, Table  1 , Table 2 , Table 3 Risk of bias in studies 18 Present assessments of risk of bias for each included study. 16-17, Figure 2 Results of individual studies 19 For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (e.g. confidence/credible interval), ideally using structured tables or plots. Table 2 , Table 3 Results of syntheses 20a For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies. 16-17

20b Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (e.g. confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect.

20c Present results of all investigations of possible causes of heterogeneity among study results. 12-16

20d Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results. n/a 24b Indicate where the review protocol can be accessed, or state that a protocol was not prepared. 9

24c Describe and explain any amendments to information provided at registration or in the protocol. 9

Support 25 Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review. 3

Competing interests 26 Declare any competing interests of review authors. 22

Availability of data, code and other materials 27 Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review. 1. "older adult*" OR elderly OR "older person*" OR senior* OR aged 2. "nursing home" OR "care home" OR "residential home" OR "extended care" OR "longterm care" OR "long-term care" OR "assisted living" OR "residential care" OR caregiver OR "social care" OR "home care" OR "home-based care" OR "respite care"

3. "artificial intelligence" OR "machine learning" OR "support vector machine" OR "neural networks" OR "vector machine" OR "machine learning" OR "deep learning" OR "ensemble learning" OR "deep network" OR "convolutional network" OR "neural network" OR "bayesian network" OR "classification tree" OR "regression tree" OR "probability tree" OR "nearest neighbor" OR "nearest neighbour" OR "fuzzy logit" OR "fuzzy logic" OR "fuzzy logistic" OR "native bayes" OR "genetic algorithm*" OR "multilayer perception" OR "random forest" OR lasso* OR kernel* OR "elastic net*" OR fuzzy OR "classification algorithm" OR "artificial neural network" OR automated OR algorithm OR wearable* OR sensor* OR "internet of things" OR robot* OR "digital human*" OR "virtual agent*" OR "conversation* agent" OR chatbot OR app 4. "randomized controlled trial" OR "controlled clinical trial" OR "pragmatic clinical trial"

OR "equivalence trial" OR "clinical trial" OR randomization OR "random allocation" OR "double-blind method" OR "double blind procedure" OR "double-blind studies" OR "singleblind method" OR "single blind procedure" OR "single-blind studies" OR placebo* OR "control group*" OR random* OR sham OR "singl* blind*" OR "singl* dumm*" OR "singl* mask*" OR "doubl* blind*" OR "doubl* dumm*" OR "doubl* mask*" OR "tripl* blind*" 5 OR "tripl* dumm*" OR "tripl* mask*" OR "trebl* blind*" OR "trebl* dumm*" OR "trebl* mask*" OR "control* study" OR "control* studies" OR "control* group*" OR "control* trial*" OR nonrandom* OR non random* OR non-random* OR quasi-random* OR quasirandom* OR allocated OR "open label study" OR "open label studies" OR "open label trial*" OR "open-label study" OR "open-label studies" OR "open-label trial" OR "phase 3"

OR "phase III" OR "equivalence study" OR "equivalence studies" OR "equivalence trial*"

OR "superiority study" OR "superiority studies" OR "superiority trial*" OR "non-inferiority study" OR "non-inferority studies" OR "non-inferiority trial*" OR "noninferiority study" OR "noninferiority studies" OR "noninferiority trial*" OR "pragmatic study" OR "pragmatic studies" OR "pragmatic trial*" OR "practical trial*" OR "quasiexperimental study" OR "quasiexperimental studies" OR "quasiexperimental trial*" OR "quasi-experimental study"

OR "quasi-experimental studies" OR "quasiexperimental trial*" 5. 1 and 2 and 3 and 4

6. Remove duplicates from 5

Web of Science ( "older adult*" OR elderly OR "older person*" OR senior* OR aged) AND ("nursing home"

OR "care home" OR "residential home" OR "extended care" OR "longterm care" OR "longterm care" OR "assisted living" OR "residential care" OR caregiver OR "social care" OR "home care" OR "home-based care" OR "respite care") AND ("artificial intelligence" OR "machine learning" OR "support vector machine" OR "neural networks" OR "vector machine" OR "machine learning" OR "deep learning" OR "ensemble learning" OR "deep network" OR "convolutional network" OR "neural network" OR "bayesian network" OR "classification tree" OR "regression tree" OR "probability tree" OR "nearest neighbor" OR "nearest neighbour" OR "fuzzy logit" OR "fuzzy logic" OR "fuzzy logistic" OR "native bayes" OR "genetic algorithm*" OR "multilayer perception" OR "random forest" OR lasso* OR kernel* OR "elastic net*" OR fuzzy OR "classification algorithm" OR "artificial neural network" OR automated OR algorithm OR wearable* OR sensor* OR "internet of things"

OR robot* OR "digital human*" OR "virtual agent*" OR "conversation* agent" OR chatbot OR app) AND ("randomized controlled trial" OR "controlled clinical trial" OR "pragmatic clinical trial" OR "equivalence trial" OR "clinical trial" OR randomization OR "random allocation" OR "double-blind method" OR "double blind procedure" OR "double-blind studies" OR "single-blind method" OR "single blind procedure" OR "single-blind studies"

OR placebo* OR "control group*" OR random* OR sham OR "singl* blind*" OR "singl* dumm*" OR "singl* mask*" OR "doubl* blind*" OR "doubl* dumm*" OR "doubl* mask*"

OR "tripl* blind*" OR "tripl* dumm*" OR "tripl* mask*" OR "trebl* blind*" OR "trebl* dumm*" OR "trebl* mask*" OR "control* study" OR "control* studies" OR "control* group*" OR "control* trial*" OR nonrandom* OR non random* OR non-random* OR quasirandom* OR quasirandom* OR allocated OR "open label study" OR "open label studies" OR "open label trial*" OR "open-label study" OR "open-label studies" OR "open-label trial" OR "phase 3" OR "phase III" OR "equivalence study" OR "equivalence studies" OR "equivalence trial*" OR "superiority study" OR "superiority studies" OR "superiority trial*" OR "noninferiority study" OR "non-inferority studies" OR "non-inferiority trial*" OR "noninferiority study" OR "noninferiority studies" OR "noninferiority trial*" OR "pragmatic study" OR "pragmatic studies" OR "pragmatic trial*" OR "practical trial*" OR "quasiexperimental study" OR "quasiexperimental studies" OR "quasiexperimental trial*" OR "quasiexperimental study" OR "quasi-experimental studies" OR "quasiexperimental trial) 

World Health Organization. Integrated care for older people (ICOPE) guidelines on community-level interventions to manage declines in intrinsic capacity evidence profile: malnutrition

World Health Organization

World Health Organization. Integrated care for older people (ICOPE) guidelines on community-level interventions to manage declines in intrinsic capacity evidence profile: mobility loss

World Health Organization

World Health Organization. Preventing and managing COVID-19 across long-term care services

World Health Organization

World Health Organization